1232 22nd Street N.W.
Washington, D.C.
20037-1202
(202) 223.2226
1 (800) 231.4222

NOF Online
Continuing Education

Update on Bisphosphonates FDA-Approved for Prevention and Treatment of Osteoporosis

 
  • Original Release Date: July 2008
  • Expiration Date: July 2010
  • Estimated Time to Complete this Educational Activity:  1.5 hours
  • Type of Enduring Material: Internet-Based CE
  • DISCLAIMER: The views and observations presented in this Continuing Education publication are those of the authors/editors and do not necessarily reflect those of the funders or producers of this publication. Readers are urged to consult current prescribing and clinical practice information in any drug, device or procedure discussed in this publication.

LEARNING OBJECTIVES

After completing this Clinical Updates you will be able to:

  • Describe the action of bisphosphonate drugs on bone
  • Compare the effectiveness of various FDA-approved bisphosphonates available for prevention and treatment of osteoporosis
  • Cite the circumstances under which it is appropriate to consider a “drug holiday” from bisphosphonate treatment
  • Discuss potential osteoporosis treatment plans tailored to fit particular patient profiles
  • Explain the criteria for assessing patient response to bisphosphonate treatment

DISCLOSURE INFORMATION
It is the policy of NOF to ensure balance, independence, objectivity, and scientific rigor in all its sponsored publications and programs. NOF requires the disclosure of the existence of any significant financial interest or any other relationship the sponsor, Editorial Board or Guest Faculty members have with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. All authors and contributors to this continuing education activity have disclosed any real or apparent commercial interest that may have direct bearing on the subject matter of this activity. EDITORIAL BOARD MEMBER DISCLOSURES

Editor-in-Chief
Angelo Licata, MD, PhD, FACP, FACE
Research Support

Merck, Lilly, Aventis, Novartis, NPS Pharmaceuticals, Procter & Gamble
Speaker
Lilly, Aventis, Procter & Gamble

Senior Editorial Consultant
Lawrence G. Raisz, MD
Research Support

Servier Pharmaceuticals
Consultant
Pfizer Laboratories, Procter & Gamble, Colgate Palmolive, Novartis

Members
Adrienne Berarducci, PhD, ARNP, BC, CCD
Grant/Research Support

Procter & Gamble Pharmaceuticals
Speakers Bureau
Procter & Gamble Pharmaceuticals

Carolyn J. Bolognese, RN
No relationships to disclose

Peggy Doheny, PhD, RN, ONC
No relationships to disclose

Vernon Herschberger, MD, ABFM
Consultant

Roche Diagnostics
Speakers Bureau

Novartis
Research Support

GlaxoSmithKline, Wyeth

Barbara Lukert, MD, FACP
Speakers Bureau

Merck, Proctor & Gamble, Eli Lilly

Paul D. Miller, MD
Research Support

Procter & Gamble, Aventis Pharmaceuticals, Roche Pharmaceuticals, Eli Lilly, Pharmacia, Merck & Co., Novartis, Pfizer, Amgen
Advisory and Speaker Boards
Procter & Gamble, Aventis, Merck, Lilly

Jeri Nieves, PhD
No relationships to disclose

Carol Sedlak, PhD, RN, ONC
No relationships to disclose

Kathy M. Shipp, PhD, PT, MHS
No relationships to disclose

Holly Thacker, MD, FACP
No relationships to disclose

NOF STAFF DISCLOSURES
Felicia Cosman, MD
Speakers Bureau

Eli Lilly, Merck
Advisory Board
Eli Lilly, Merck, Novartis, NPS Pharmaceuticals

Susan Randall, RN, MSN, FNP-BC
No relationships to disclose

Audrey Shively, MSHSE, CHES
No relationships to disclose

Kelly Trippe, MA
No relationships to disclose.

Click Here for Article

Click Here for Self-Assessment

Software Requirement: Adobe Acrobat Reader is required to read the text for this continuing education activity.

If you do not have Adobe Acrobat Reader, click here.

Copyright 2008 National Osteoporosis Foundation. All Rights Reserved.
Please read our legal disclaimer, privacy statement and reprint policy.
To report problems with this site, please contact: